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Table 1. Cumulative incidence (CI) of neutrophil engraftment
andmedian day toANC>0.5 according to day 21 bonemarrow
S224 Poster Session IMethods:The study cohort consists of 117 consecutive patients (28
matched siblings, 25 unrelated and 64 haplo) with 115 leukemia, 1
SAA, and 1 NHL. The median age is 20 years (3-62). Conditioning
regimens: 1) Ara-C1BUCY (n5 14); 2) Ara-C1 BUFlu (n5 12). In
addition, Haplo and URD received either 3) Ara-C1 BUCY1ATG
(n 5 54) or, 4) Ara-C1BUFlu1ATG. (n 5 32) followed by unma-
nipulated G-CSF mobilized bone marrow and/or peripheral blood
(G-BMPBorG-PB). 5 patients used other regimen.GVHDprophy-
laxis: CSA, MMF and short-term MTX. Multiple linear regression
models were used for cost analysis. Variables considered were: trans-
plant type (Sibling vs. URD vs. Haplo), quality of life (QOL), D/R
sex match, patient age by decade, comorbidity, diagnoses, disease
status pre-transplant, conditioning regimen, graft type, MNC,
CD341cells, ANC and platelet engraftment, AGVHD and death.
Results: The median follow-up was 603 days (range 62 -1134).
Clinical outcomes are shown in the following table.
Table 1. Clinical Outcomes after transplantation
Sibling URD Haplo P composition and chimerism (n 5 56).P ValueTRM 100 day 0 (0-0)% 9 (2-24)% 5 (1-12)% 0.0634Day 21 BM CI Engraftment by BM Characteristic for CITRM 1 year 12 (3-27)% 15 (4-32)% 14 (7-24)% 0.9488Characteristic Sub-group (Day ANC $ 0.5) (RR , p value) ComparisonRelapse 100 day 11 (3-25)% 4 (0-16)% 3 (1-10)% 0.4640
Relapse 1 year 23 (10-40)% 19 (9-41)% 9 (3-18)% 0.2187% Total Myeloid <10% (n518) 10-50% (n518) >50% (n520) 0.017DFS 100 day 89 (70-96)% 87 (65-96)% 92 (82-97)% 0.7817Precursors 95% (27 days) 89% (27 days) 100%(22 days)DFS 1 year 65 (43-80)% 67 (37-84)% 77 (63-86)% 0.4721in Aspirate (RR 0.44, (RR 0.47, ReferenceSurvival 100 day 96 (77-99)% 91 (69-98)% 94 (84-98)% 0.7430(n556) p50.017) p50.028)Survival 1 year 84 (63-94)% 78 (49-91)% 83 (70-90)% 0.8780% Cellularity
in Core
(n556)
<5% (n521)
91% (30 days)
(RR 0.39,
p50.005)
5-9% (n515)
100% (27 days)
(RR 0.83,
p50.596)
>10% (n520)
95%(21 days)
Reference
0.005
% Total Donor
Chimerism
(n556)
<90% (n56)
67% (38 days)
(RR 0.16,
p50.001)
90-99% (n59)
100% (29 days)
(RR 0.42,
p50.026)
100% (n541)
98% (22 days)
Reference
0.001The overall median cost (range) within 100-day of transplant was
52,373USD (13,627 – 262,716). The mean cost (95% CI) of HLA
matched sibling, URD and haplo was 59,015 USD (45,537-
72,493), 61,970 USD (47,701-76,224) and 63,373 USD (54,463-
72,284) (P 5 0.8674), respectively. Multivariate cost analysis
indicated that QOL# 80, conditioning including Flu or Flu1ATG
and acute GVHD 2-4 correlated with increased cost.
Conclusion: These data suggest that transplant type (Sibling vs.
URD vs. Haplo) does not significantly effect on the clinical out-
comes and 100-day cost of transplantation. Future studies with
more patients and longer follow-up are warranted.193
TOTAL DONOR CHIMERISM IN THE DAY 21 BONE MARROW PREDICTS
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Malaspina, H.1, Kernan, N.A.2, Scaradavou, A.2, Hedvat, C.3,
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Delayed or failed engraftment is a concern after CBT, even when
using double unit grafts. Therefore, we analyzed the ability of the day
21 bone marrow (BM) composition and percent donor chimerism to
predict sustained donor neutrophil engraftment in 56 recipients of
myeloablative double unit CBT. Patients (median age 29 years,
range 2-64) were transplanted for hematological malignancies, pre-
dominantly acute leukemia. Units had infused cell doses of 2.7 
107 TNC/kg/ 1.2  105 CD341 cells/kg for the larger unit, and
1.9  107 TNC/kg/ 0.7  105 CD341 cells/kg for the smaller
unit, with a donor-recipient HLA-match of 6/6 (n3), 5/6 (n59),
and 4/6 (n50). The cumulative incidence (CI) of neutrophil engraft-
ment was 95% (95% confidence interval: 89-100), with 47 patients
engrafting with 1 unit and 6 engrafting with 2. The percentage of to-
tal myeloid precursors in the day 21 BMaspirate (median 40%, range
0-87), and the percent cellularity in the day 21 BM biopsy (median
5%, range 0-80), were both associated with neutrophil engraftment
(Table 1). However, the most critical predictor of engraftment was
the percent total donor chimerism (unit#1 1 unit#2, median
100%, range 65-100), regardless if 1 or 2 units were present (Table
1). Sustained engraftment was seen in 98% of the 41 patients who
were 100% donor at day 21 with a median day to absolute neutrophil
count (ANC) $ 0.5 of 22 days. By contrast, only 87% of the 15 pa-
tients\ 100% total donor engrafted [median day to ANC $ 0.5 31days with a relative risk (RR) 0.3, p 5 0.001]. Patients who were
\90% donor had especially poor engraftment (Table 1). The asso-
ciation between total donor chimerism and engraftment was inde-
pendent of the percentage of myeloid precursors or BM cellularity.
In patients (n 5 37) without engraftment by day 21, a sub-group
of particular clinical concern, day 21 total donor chimerism was
also significantly associated with subsequent engraftment success
(p5 0.003). No patient demographic was associated with total donor
chimerism, and the only significant graft characteristic was the in-
fused CFU dose of the engrafting unit (p 5 0.002). These findings
demonstrate the critical importance of the day 21 BM total donor
chimerism and are of practical significance in the care of double
unit CBT recipients. Further, they give interesting insights into dou-
ble unit biology and suggest that the hematopoietic potential of the
engrafting unit underlies the ability to generate complete donor chi-
merism.194
THE T-CELL EPITOPE (TCE) ALGORITHM FOR CLASSIFYING HLA-DPB1
MISMATCHES DOES NOT PREDICT CLINICAL OUTCOMES IN HSCT
Askar, M., Flanagan, P., Rybicki, L., Kalaycio, M., Pohlman, B.,
Andresen, S., Dean, R., Duong, H., Copelan, E., Bolwell, B., Sobecks, R.
Cleveland Clinic
A number of reports suggested the relevance of HLA-DPB1
matching for the outcomes of allogeneic hematopoietic stem cell
transplantation (HSCT). An algorithm for determining DPB1 mis-
match permissiveness based on T-Cell Epitopes (TCE) has been
proposed (Zino et al, Blood 2004). According to this algorithm, all
DPB1 alleles are categorized in 3 (TCE3) or 4 (TCE4) groups based
on antigenicity. Accordingly DPB1 mismatches are classified as
permissive; non-permissive in GvHD; or non-permissive in HvG
direction.
Objective: To determine whether TCE classification is associated
with HSCT outcomes. The outcomes considered in this analysis are
failure to engraft, acute GvHD, chronic GvHD, and overall survival.
Methods:We analyzed 144 unrelated donor ($ 7/8 allelematches at
A, B, C, DRB1) allogeneic transplants performed in our center be-
tween 1999-2009. HLA-DPB1 mismatches were assessed using
both TCE3 and TCE4 versions of the algorithm. Recursive parti-
tioning analysis with a log-rank splitting method was used to catego-
rize TCE variables into groups that best predict each outcome. Cox
proportional hazards analysis was used to identify prognostic factors
for each outcome.
Results:Graft failure was significantly highest among recipient with
permissive DPB1 mismatches (AHR 9.87, 95% CI 1.21-80.3, P 5
0.03) compared to recipients of zero mismatched, GvHD non-per-
missive, and HvG nonpermissive DPB1 mismatched donors. Acute
GvHD was significantly higher in all DPB1 mismatches regardless
of TCE classification (AHR 1.93, 95%CI 1.11-3.34, P5 0.02) com-
pared zeroDPB1mismatch. There was no significant association be-
tween TCE classification and chronic GvHD, or overall survival.
